enGene Therapeutics Inc. ENGN
1.69 USD +0.02 (+1.25%)
Nov 11, 2026, 11:41 AM EST
1.63 Day range 1.70
1.40 52-week range 12.25
- YTD
- -81.27%
- 1 year
- -80.83%
News
businesswire.com enGene to Participate in Upcoming Investor Conferences BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will…
defenseworld.net enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Price Target of $11.05 According to Brokerages enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned an average recommendation of "Hold" from the fourteen research firms that are presently covering the stock, MarketBeat Ratings…
benzinga.com Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Market Perform.- benzinga.com enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of…
benzinga.com EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential
benzinga.com This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.
benzinga.com Morgan Stanley Downgrades enGene Therapeutics to Underweight Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Underweight.
benzinga.com W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey.…
benzinga.com HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4 HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $6 to $4.- benzinga.com EnGene Therapeutics Implements Workforce Reduction Of About 50% In June 2026; CFO Ryan Daws To Depart From Co, Effective July 15, 202 Recent Corporate UpdatesReduction in Force and Executive Departures: In June 2026, enGene implemented a plan to reduce its workforce by approximately 50% to streamline operations and preserve cash.…
- benzinga.com enGene Holdings Q2 EPS $(0.43) Beats $(0.47) Estimate enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.47) by 8.51 percent. This is a 15.69 percent increase over losses of…
benzinga.com Why Is enGene Therapeutics Stock Falling Friday? enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash price forecasts as the sell-off intensifies.- benzinga.com Citizens Downgrades enGene Therapeutics to Market Perform Citizens analyst Silvan Turkcan downgrades enGene Therapeutics (NASDAQ:ENGN) from Market Outperform to Market Perform.
- benzinga.com Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2 Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Equal-Weight and lowers the price target from $25 to $2.
- benzinga.com HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $6 HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $25 to $6.
- benzinga.com Piper Sandler Downgrades enGene Therapeutics to Neutral, Lowers Price Target to $4 Piper Sandler analyst Allison Bratzel downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Neutral and lowers the price target from $7 to $4.
benzinga.com Dow Dips 350 Points; US Foods Posts Downbeat Earnings Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US Foods reports lower Q1 earnings and sales. Agilon Health, Aaon, and Rackspace Technology see gains…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com US Stocks Mixed; Dow Falls Over 100 Points US stocks higher Thursday morning, Dow down 0.28%, Nasdaq up 0.50%, S&P 500 up 0.07%. Tech sector up 1.1%, energy sector down 2.8%. McDonald's reports strong earnings and sales.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com WBB Securities Initiates Coverage On enGene Therapeutics with Buy Rating, Announces Price Target of $21.5 WBB Securities analyst Karen Sterling initiates coverage on enGene Therapeutics (NASDAQ:ENGN) with a Buy rating and announces Price Target of $21.5.
- benzinga.com enGene Holdings To Change Its Corporate Name To enGene Therapeutics Effective April 8 Name change reflects transition towards potential commercial organization in 2027Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026enGene Therapeutics Inc. (formerly,…
- benzinga.com Oppenheimer Maintains Outperform on enGene Holdings, Lowers Price Target to $30 Oppenheimer analyst Leland Gershell maintains enGene Holdings (NASDAQ:ENGN) with a Outperform and lowers the price target from $33 to $30.
benzinga.com HC Wainwright & Co. Reiterates Buy on enGene Holdings, Maintains $25 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with a Buy and maintains $25 price target.- benzinga.com enGene Holdings Q1 EPS $(0.44) Beats $(0.58) Estimate enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.58) by 24.53 percent. This is a 8.33 percent increase over losses of…
- benzinga.com enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.3 percent. This is a 114.71 percent decrease over losses of…
benzinga.com enGene Holdings Says FDA Selects Detalimogene Voraplasmid To Participate In Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program enGene one of nine companies awarded CDRP per yearProgram aims to support CMC development of products with expedited clinical development timeframes and provide patients with earlier access to these…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Morgan Stanley Maintains Overweight on enGene Holdings, Raises Price Target to $19 Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and raises the price target from $18 to $19.
benzinga.com Oppenheimer Reiterates Outperform on enGene Holdings, Raises Price Target to $33 Oppenheimer analyst Leland Gershell reiterates enGene Holdings (NASDAQ:ENGN) with a Outperform and raises the price target from $30 to $33.- benzinga.com UBS Maintains Neutral on enGene Holdings, Raises Price Target to $10 UBS analyst Colin Bristow maintains enGene Holdings (NASDAQ:ENGN) with a Neutral and raises the price target from $4 to $10.
- benzinga.com Citizens Maintains Market Outperform on enGene Holdings, Raises Price Target to $21 Citizens analyst Silvan Tuerkcan maintains enGene Holdings (NASDAQ:ENGN) with a Market Outperform and raises the price target from $18 to $21.
benzinga.com Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.
benzinga.com PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- benzinga.com Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial
- benzinga.com Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures trading higher by around 70 points on Thursday.
- benzinga.com Dow Edges Higher; QuidelOrtho Shares Plummet U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.11% to 38,313.27 while the NASDAQ rose 0.70% to…
- benzinga.com Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list…
benzinga.com Crude Oil Moves Lower; Louisiana-Pacific Posts Upbeat Earnings U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Wednesday. The Dow traded down 0.20% to 38,194.62 while the NASDAQ rose 0.19% to 15,686.43. The S&P…- benzinga.com Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.